OS-ST-HER2医薬品は肺変性腫の再発を防止する 有望な結果を示している OS Therapies' OST-HER2 drug shows promising results in preventing lung metastatic osteosarcoma recurrence.

OS-HER2のフェーズ2bの研究結果から 陽性の結果が報告されました OS-HER2の免疫療法薬で 肺変性腫の再発を防いだのです OS Therapies has reported positive outcomes from their Phase 2b study for OST-HER2, an immunotherapy drug for preventing recurrent lung metastatic osteosarcoma. この研究は主な目標に適合し,12ヶ月のイベントフリーサバイバル率が33.3%を達成し,歴史的な20%よりも著しく高い. The study met its primary goal, showing a 33.3% event-free survival rate at 12 months, significantly higher than the 20% historical rate. この里程標は,当該企業の株式価格の50%以上を前市場取引で増した. This milestone led to a more than 50% increase in the company's stock price in pre-market trading.